Clinical trials: bipolar
Bipolar Disorder, Schizophrenia
COMpassion for Psychiatric Disorders And Self-Stigma
People with mental disorders face frequent stigmatizing attitudes and behaviors from others . In response to this, they tend to isolate themselves, with the risk of impeding care and the process of recovery and integration into…
- Conditions
- Bipolar Disorder, Schizophrenia, Depression, Borderline Personality Disorder
- Trial name
- COMPASS (NCT05698589)
- Testing
- Compassion Focused Therapy, Ending Self Stigma
- Where
- 7 sites in France
- Volunteers
- 336 people
- Sponsor
- University Hospital, Strasbourg, France
Schizophrenia, Schizoaffective Disorder
Enhancing Veteran-Clinical Collaboration in VA PRRCs
Over 60% of Veterans with serious mental illness have a service-connected disability that impairs their ability to work, go to school, and/or have successful personal lives.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Delusional Disorder, Bipolar Disorder
- Trial name
- EVCC VPRRC (NCT06898879)
- Testing
- Collaborative Decision Skills Training, Leveling Up
- Where
- 3 sites in United States
- Volunteers
- 119 people
- Sponsor
- VA Office of Research and Development
Bipolar Disorder I
Melatonin and Response to Lithium
Bipolar disorders are mental illnesses characterized by the recurrence of mood-episodes, that can have a severe impact on the life of individuals.
- Trial name
- MeLiR (NCT05878730)
- Testing
- urine collection, Level of Proteins, Level of mRNA and miRNA
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Bipolar I Disorder, Psychosis
Ketogenic and Nutritional Interventions for First Episode Bipolar Disorder
This is a randomized, controlled clinical trial to assess the effects of the ketogenic diet in combination with treatment as usual on brain energy metabolism and psychiatric symptoms in individuals with first episode bipolar…
- Conditions
- Bipolar I Disorder, Psychosis, Schizoaffective Disorder
- Trial name
- NCT06221852
- Testing
- Ketogenic diet, Dietary Guidelines for Americans
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mclean Hospital
Bipolar I Disorder, Schizoaffective Disorder
Open Label Extension Study of NCT06221852
This is a 12-week open-label extension study for participants completing study NCT06221852.
- Conditions
- Bipolar I Disorder, Schizoaffective Disorder, Psychosis
- Trial name
- NCT06558201
- Testing
- Ketogenic diet
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mclean Hospital
Bipolar Depression
Ketogenic Intervention for Bipolar Depression
The purpose of this study is to assess the clinical correlates of therapeutic precision ketosis in bipolar depression and to evaluate the cardiometabolic correlates associated with therapeutic precision ketosis in bipolar…
- Trial name
- NCT07121894
- Testing
- Ketogenic Diet
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Bipolar Disorder (BD)
Project MOVE Bipolar
The investigators propose a randomized clinical trial in which 24 individuals with bipolar disorder are assigned to one of three arms, with each successive arm having an added component that may serve to increase and maintain…
- Trial name
- NCT07767032
- Testing
- BA, SHE, HE
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Butler Hospital
Major Depressive Disorder, Post-Traumatic Stress Disorder
Examination of Glutamate and mGluR5 in Psychiatric Disorders
This research study is designed to look at the involvement of the glutamate system in depression. Each subject will undergo a screening appointment to determine study eligibility.
- Conditions
- Major Depressive Disorder, Post-Traumatic Stress Disorder, Bipolar Disorder
- Trial name
- NCT02727972
- Testing
- Cognitive Testing, MRI, PET
- Where
- United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Yale University
Bipolar I Disorder, Schizophrenia
Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects
To evaluate the long-term safety and tolerability of OLZ/SAM in pediatric subjects with schizophrenia or Bipolar I disorder
- Trial name
- NCT04987229
- Testing
- OLZ/SAM
- Where
- 35 sites in United States, Argentina and 3 more
- Volunteers
- 236 people
- Sponsor
- Alkermes, Inc.
Schizophrenia, Bipolar I Disorder
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
To compare changes in body mass index (BMI) Z-score following treatment with OLZ/SAM vs olanzapine
- Trial name
- NCT05303064
- Testing
- OLZ/SAM, Olanzapine
- Where
- 47 sites in United States, Argentina and 3 more
- Volunteers
- 220 people
- Sponsor
- Alkermes, Inc.
Bipolar I Disorder, Bipolar II Disorder
A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United States.
- Trial name
- NCT06696755
- Testing
- Icalcaprant
- Where
- 33 sites in United States
- Volunteers
- 195 people
- Sponsor
- AbbVie
Bipolar Depression
A Trial of the Fatty Acid Amide Hydrolase Inhibitor Palmitoylethanolamide in Bipolar Depression
The purpose of this study is to o evaluate the antidepressant efficacy of the PEA in Bipolar Depression and the association between antidepressant response with endogenous cannabinoids and cytokine levels
- Trial name
- NCT06229977
- Testing
- Palmitoylethanolamide (PEA), Treatment as Usual (TAU)
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Rodrigo Machado-Vieira, MD, PhD, MSc
Major Depressive Disorder, Bipolar Disorder
Transcranial Electric Stimulation Therapy (TEST) for Treatment Resistant Depression (TRD)
Background: People with TRD are often helped by electroconvulsive therapy (ECT). But ECT can affect memory and thinking. Researchers want to study a treatment called TEST that uses less electricity.
- Conditions
- Major Depressive Disorder, Bipolar Disorder, Unipolar Major Depression
- Trial name
- NCT05172271
- Testing
- MagPro TMS Stimulator and coil, Thymatron(R) System IV, Magnetic Resonance Imaging Scanner
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Institute of Mental Health (NIMH)
Bipolar II Disorder, Depression, Bipolar
Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality
The purpose of the study is to assess the safety and acceptability of up to two sequential administrations of 25 mg psilocybin with additional therapeutic support in decreasing suicidality in patients with Bipolar Disorder (BD…
- Conditions
- Bipolar II Disorder, Depression, Bipolar, Suicidality
- Trial name
- NCT06706232
- Testing
- Psilocybin, Therapeutic Support
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- The University of Texas Health Science Center, Houston
Serious Mental Illness, Psychotic Disorder
Changing Lives and Changing Outcomes-9 at Worcester Recovery Center and Hospital
People with serious mental illness (depression, bipolar, and schizophrenia spectrum disorders) have high rates of repeated criminal legal involvement and psychiatric hospitalizations.
- Conditions
- Serious Mental Illness, Psychotic Disorder, Depression, Bipolar
- Trial name
- CLCO-9 (NCT07359157)
- Testing
- Changing Lives and Changing Outcomes-9
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
Agitation Associated With Bipolar Disorder, Agitation,Psychomotor
Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder
This is a definitive study to support the safety and efficacy evaluation of BXCL501 for the acute treatment of agitation in bipolar disorder.
- Conditions
- Agitation Associated With Bipolar Disorder, Agitation,Psychomotor, Bipolar Disorder
- Trial name
- SERENITY II (NCT04276883)
- Testing
- Sublingual film containing Dexmedetomidine (BXCL501)
- Where
- 15 sites in United States
- Volunteers
- 380 people
- Sponsor
- BioXcel Therapeutics Inc
Schizophrenia, Schizo-Affective Disorder
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
This is a study of the efficacy and safety of BXCL501 in children and adolescents with acute agitation and either bipolar disorder or schizophrenia.
- Conditions
- Schizophrenia, Schizo-Affective Disorder, Schizophreniform; Schizophrenic, Bipolar Disorder I
- Trial name
- NCT05025605
- Testing
- BXCL501 80 Micrograms, BXCL501 120 Micrograms, BXCL501 60 Micrograms
- Where
- 5 sites in United States
- Volunteers
- 140 people
- Sponsor
- BioXcel Therapeutics Inc
Bipolar Disorder, Schizophrenia
Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder
This is an in-clinic, single arm, open-label study assessing tachyphylaxis, tolerance, and withdrawal following repeated doses of Igalmi in adult males and females with agitation associated with schizophrenia or bipolar disorder.
- Conditions
- Bipolar Disorder, Schizophrenia, Agitation,Psychomotor, Schizo Affective Disorder
- Trial name
- NCT06041646
- Testing
- Sublingual film containing Igalmi
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- BioXcel Therapeutics Inc
Bipolar Depression
Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression
This study is an open-label, single-arm, proof-of-concept study, wherein treatment resistant bipolar depression (TRBD) participants will receive one 25 mg dose of oral psilocybin accompanied by preparatory, monitoring, and…
- Trial name
- Psilo-BD (NCT06506019)
- Testing
- Psilocybin, Functional MRI
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University Health Network, Toronto
Agitation,Psychomotor, Bipolar I Disorder
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)
In this study, an investigational medication named BXCL501 is being tested for the treatment of episodes of agitation associated with bipolar I and bipolar II disorder, schizophrenia, schizoaffective and schizophreniform…
- Conditions
- Agitation,Psychomotor, Bipolar I Disorder, Bipolar II Disorder, Schizophrenia
- Trial name
- NCT05658510
- Testing
- BXCL501
- Where
- 24 sites in United States
- Volunteers
- 452 people
- Sponsor
- BioXcel Therapeutics Inc